Stephen Mathai, MD
Enriched profileProfessor of Medicine; Director, Inpatient Pulmonary Service, Johns Hopkins Hospital · Johns Hopkins University School of Medicine
Stephen Mathai is Professor of Medicine; Director, Inpatient Pulmonary Service, Johns Hopkins Hospital at Johns Hopkins University School of Medicine. OpenAlex indexes 387 publications with 11,923 citations (h-index 55); ClinicalTrials.gov lists 1 registered study with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Pulmonary Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Stephen C. Mathai, MD MHS, is Professor of Medicine at Johns Hopkins University School of Medicine. The public record shows 387 publications with 11,923 citations (h-index 55), centered on Respiratory. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 3 companies, 3 NIH-funded awards (2006–2019).
- Most recent indexed publication: 2026 · bioRxiv
- Top research focus: Respiratory
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Research focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 26 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Sponsor: Johns Hopkins University
Industry payments
Updated 27 Aug 2026
3 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202518 payments$15,072openpaymentsdata.cms.gov ↗
- United Therapeutics CorporationProgram year20252 payments
- Merck Sharp & Dohme LLCProgram year202421 payments$30,118openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
65.3%Endothelin Receptor Antagonist34.1%Ambrisentan77%Opsumit23%Part D<11 patientsSoluble Guanylate Cyclase Stimulator16.1%Adempas100%Part D<11 patientsGenitourinary & hormones
17.7%Phosphodiesterase 5 Inhibitor17.7%Sildenafil Citrate61%Tadalafil39%Part D<11 patientsBlood & clotting
14%Factor Xa inhibitor5.9%Xarelto100%Part D<11 patientsProstacycline Vasodilator4.3%Orenitram Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2006–2019 per NIH RePORTER. The latest:
- Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics Program
Johns Hopkins University
FY2019$248,442U01HL125175 - Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics Program
Johns Hopkins University
FY2018$330,615U01HL125175 - Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics Program
Johns Hopkins University
FY2017$157,394U01HL125175
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension.
The European respiratory journal
Article2026 - Metabolomics of Right Ventricular Function in Pulmonary Hypertension.
Circulation research
Article2026
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/stephen-mathai-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
phaware.medium.com/im-aware-that-i-m-rare-steve-mathai-md-52c652f73d6c
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.medium.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- Board Certified
Pulmonary Disease and Critical Care Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- Chair
Pulmonary Vascular Disease Network, American College of Chest Physicians
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - Member
Scientific Leadership Council, Pulmonary Hypertension Association; National Chairperson, Preceptorship Program Planning Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pcori.org ↗ - Member
American Thoracic Society (Pulmonary Circulation Assembly Program and Nominations Committees)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →wsphassociation.org ↗
Awards & honors
honors on the public record- Frederick L. Brancati Award for Mentorship
Department of Medicine, Johns Hopkins
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthcare4ppl.com ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
Ann Dana Kusch Multidisciplinary Program for Interstitial Lung Disease and Pulmonary Hypertension Research, Johns Hopkins
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Media & interviews
press, podcasts and appearances- phaware podcast
Episode 112 "I'm Aware That I'm Rare" (Part 2), discussed scleroderma-associated pulmonary hypertension and clinical trials
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmonaryhypertensionnews.com ↗ - Pulmonary Hypertension Roundtable: PH and Connective Tissue Disease
Advances in Pulmonary Hypertension journal roundtable
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →meridian.allenpress.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Kenneth Pienta, MD
Johns Hopkins University School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Harry Quigley, MD
Johns Hopkins University School of Medicine